SHL Telemedicine

SHL develops and operates an integrated remote-care system. SmartHeart is a portable, hospital-grade 12-lead ECG device that can be used by a patient or a clinician, paired over Bluetooth with a mobile device, and transmitted to a remote location for professional review. The company's published safety information describes a workflow in which compatible software assembles the ECG and rhythm strip record for review by a medical professional. SmartHeartPro adds cloud storage and access to SHL's clinical service, with the company stating that its telemedicine-center staff can return findings within no longer than 15 minutes. This is materially different from a single-lead wearable or a generic video visit: it combines a fuller cardiac signal with a defined interpretation and escalation process.

The broader platform includes the Central Communication Module (CCM), which transmits readings from supported devices over internet, cellular, or landline connections. SHL lists blood pressure, weight, oxygen saturation, breathing, and glucose-related monitoring among the connected measurements, allowing readings to be compared with baselines and associated with a personal health record. The company says it operates 24/7 telemedicine centers in Israel and Germany and provides global cloud-based services, with approximately three million interactions and data readings annually. The operating model is therefore a hybrid of regulated medical-device technology, communications infrastructure, software, and clinical labor; service quality depends on the whole chain working reliably.

SHL serves consumer, professional, and institutional healthcare use cases. Its Israeli business is the largest revenue contributor, while Germany is a significant operating market and the United States remains a distribution and commercialization effort. In 2025, management described a shift in the US toward corporate and public entities, physicians, small clinics, and other business channels for SmartHeart. The 2025 annual report records USD 58.694 million of revenue, USD 3.385 million of adjusted EBITDA, and a USD 15.377 million net loss. Revenue increased in reported dollars, but management also reported a constant-currency decline and a USD 2 million reduction in German revenue. The figures demonstrate a real operating base and improving adjusted profitability, not a proven high-growth or consistently profitable software business. The report also describes a USD 15 million capital raise and write-offs of capitalized software, making liquidity, capital allocation, and the replacement of legacy systems important diligence topics.

Competition is broad and asymmetric. AliveCor and other cardiac-monitoring specialists compete for ECG workflows; iRhythm and similar vendors compete in ambulatory monitoring; Philips and GE HealthCare compete through hospital and remote-patient-monitoring portfolios; Teladoc and other virtual-care platforms compete for the service relationship; and hospitals can retain ECG interpretation and triage in-house. SHL's likely edge is the accumulated integration of portable full 12-lead acquisition, transmission, patient records, monitoring-center procedures, and clinical escalation. That edge is operational and relationship-based rather than an obviously unassailable hardware moat. It must be tested against reimbursement, workflow integration, device replacement cycles, clinical turnaround, customer retention, and the lower friction of increasingly capable wearables.

The defense and national-security case is credible but bounded. A portable full 12-lead ECG plus remote professional review could support medical triage for remote bases, maritime crews, disaster-response teams, humanitarian missions, and other sites without an on-site cardiologist. Multiple transmission paths and cloud workflows may help where specialist access is scarce. However, no verified military customer, defense deployment, government contract, or austere-environment validation is asserted in this record. Any defense relevance remains an adjacency requiring diligence on ruggedization, power, satellite or degraded-connectivity operation, cybersecurity, data sovereignty, clinical liability, offline procedures, response-time guarantees, and procurement eligibility. The company should therefore be treated as a mature dual-use reference and potential capability partner, not as a demonstrated defense supplier.